NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OncoC4, Inc.

OncoC4, Inc.

Private
Rockville, MarylandHealthcare & Life Scienceshttps://oncoc4.com/en/

Last Round

Series B

Oct 2, 2025

Est. Valuation

$660M

Total Funding Raised

$250M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OncoC4, Inc. is a clinical-stage biotechnology company that discovers and develops novel biologics for the treatment of cancer and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cancer immunotherapycheckpoint inhibitorsanti-CTLA-4 antibodyimmuno-oncologyclinical-stage biotechmonoclonal antibodysolid tumorsbiopharma partnershipsdrug licensingregulatory T cellsTregstumor microenvironmentbispecific antibodyneurodegenerative diseasesCAR T-cell therapyCAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoC4, Inc. Comps

Public and private peers based on sector, stage, and business model.

OncoC4, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

OncoC4, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 2, 2025
StrategicMar 20, 2023

Key People

Founding team and executive leadership

Yang Liu

Chairman, CEO And CSO

Executive Team

Shiniu Wei

Chief Financial Officer

Executive Team

Helen Schiltz

Chief Operating Officer

Executive Team

Martin Devenport

COO

Executive Team

OncoC4, Inc. Investors

Notable investors and investment history

OncoC4, Inc. investors
InvestorRounds
Bencao CapitalSeries B
Kaitai CapitalSeries B
Greater Bay Area HomelandSeries B
HM Venture PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 40% MoM, reaching 6.1K.

  • Jan 20, 2026

    Monthly visitors grew 191% MoM, reaching 7.4K.

OncoC4, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OncoC4, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OncoC4, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range68
Year Founded2020
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.